Stock Price Quote

SYNCOM FORMULATIONS (INDIA) LTD.

NSE : SYNCOMFBSE : 524470ISIN CODE : INE312C01025Industry : Pharmaceuticals & DrugsHouse : Private
BSE13.070.03 (+0.23 %)
PREV CLOSE ( ) 13.04
OPEN PRICE ( ) 13.00
BID PRICE (QTY) 13.02 (1953)
OFFER PRICE (QTY) 13.08 (2052)
VOLUME 69364
TODAY'S LOW / HIGH ( )12.91 13.09
52 WK LOW / HIGH ( )12.78 23.46
NSE13.030.01 (+0.08 %)
PREV CLOSE( ) 13.02
OPEN PRICE ( ) 12.90
BID PRICE (QTY) 13.03 (94)
OFFER PRICE (QTY) 13.05 (8200)
VOLUME 457553
TODAY'S LOW / HIGH( ) 12.90 13.08
52 WK LOW / HIGH ( )12.8 23.49
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 21-06 1988
Management Info
Ankit Kedarmal Bankda - Chairman Vijay Shankarlal Bankda - Managing Director
Registered Office

Address 7 Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E),
Mumbai,
Maharashtra-400093

Phone 022 30887744 / 54

Email sfil87@syncomformulations.com

Website www.sfil.in

Registrars Details
Ankit Consultancy Pvt Ltd
Plot No 60,Electronic Complex,Pardeshipura,Indore
Listing : BSE, NSE

NEWS

03Jan Syncom Formulations India informs abou
Syncom Formulations India has informed that it enclosed announcement in..
11Feb Syncom Formulations (India) submits ne
Pursuant to Regulation 30 read with Schedule III Part A(A) and in compli..
02Jul Syncom Formulations (India) informs ab
Syncom Formulations (India) has informed that the Share Transfer Agent o..
09May Syncom Formulations (India) submits bo
Syncom Formulations (India) has informed that pursuant to Regulation 29(..
05Apr Syncom Formulations (India) informs ab
Syncom Formulations (India) has informed that it enclosed Certificate fo..

Financials

in Millions
QTR Sep 25 ANNUAL 25
Net Profit168.42488.72
Gross Profit 223.58 646.59
Operating Profit 239.58706.97
Net Sales 1214.354628.49

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Astrazeneca Pharma I (BSE)
peergroup  8317.00 (1.28%)
M.Cap ( in Cr)20555.63
Fredun Pharma (BSE)
peergroup  1550.00 (3.59%)
M.Cap ( in Cr)809.20
Torrent Pharma (BSE)
peergroup  3981.95 (1.08%)
M.Cap ( in Cr)133406.73
Acutaas Chemicals (BSE)
peergroup  1725.10 (2.50%)
M.Cap ( in Cr)14213.24
Aarti Pharmalabs (BSE)
peergroup  802.35 (4.64%)
M.Cap ( in Cr)6945.40

Shareholding Pattern

PROMOTERS 50.57%
NON-INSTITUTION 49.17%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Syncom Formulations (India) Ltd.

Syncom Formulations (India) Ltd. was incorporated in the year 1988. Its today's share price is 13.07. Its current market capitalisation stands at Rs 1221.06 Cr. In the latest quarter, company has reported Gross Sales of Rs. 4628.49 Cr and Total Income of Rs.4800.41 Cr. The company's management includes Ankit Kedarmal Bankda, Ankit Jain, Ritesh Kumar Lunkad, Ruchi Jindal, Kedarmal Bankda, Vijay Shankarlal Bankda, Vaishali Agrawal.

It is listed on the BSE with a BSE Code of 524470 , NSE with an NSE Symbol of SYNCOMF and ISIN of INE312C01025. It's Registered office is at 7 Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E)Mumbai-400093, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Sanjay Mehta & Associates, SP Moondra & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.